{"disease":{"id":"lung-cancer-locally-advanced-or-metastatic","name":"lung cancer locally advanced or metastatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07461662","title":"Evaluation of Endobronchial Ultrasound Needle Cleaning Techniques and Their Impact on Specimen Contamination","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":204,"lead_sponsor_name":"University of Mississippi Medical Center","has_results":false},{"nct_id":"NCT07583316","title":"A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Corregene Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT03911219","title":"Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT07202364","title":"A Study of YL202 in Patients With Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"MediLink Therapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT05919537","title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Hummingbird Bioscience","has_results":false},{"nct_id":"NCT07260058","title":"Immune Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","has_results":false},{"nct_id":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT04770688","title":"Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07457541","title":"Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Tomsk National Research Medical Center of the Russian Academy of Sciences","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}